SynthesisFrontiers in psychiatry2026
GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Research on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and psychiatric outcomes has expanded rapidly following the clinical success of semaglutide, pharmacoepidemiological signals on psychiatric adverse events, and growing regulatory scrutiny, yet the intellectual structure and thematic evolution of this interdisciplinary field remain uncharacterised. We aimed to map publication trends, conceptual structure, thematic evolution, and collaboration networks of research on GLP-1 RAs and psychiatric outcomes. Methods: Bibliographic records were retrieved independently from OpenAlex, Lens.org, and PubMed (MEDLINE) on 8 April 2026, using parallel Boolean searches restricted to title and abstract fields. After cross-database deduplication and cleaning, 2, 197 documents (1990--2026) were retained. Performance analysis, science mapping (keyword co-occurrence, collaboration networks), and thematic analysis (Callon's centrality-density map, thematic evolution) were performed using the bibliometrix R package. Results: The field showed exponential growth, with annual output rising from fewer than 10 publications before 2004 to nearly 500 in 2025. The corpus spanned 1, 063 journals, 9, 269 authors, and 85 countries (h-index 101; mean 21.9 citations/document). Thematic mapping placed depression in the niche themes quadrant (high density, low centrality), while obesity and diabetes mellitus occupied the basic themes quadrant. Thematic evolution showed depression emerging as a distinct research front only in 2022--2026. Discussion: Depression research within the GLP-1 RA literature has developed internal coherence as a niche theme but remains peripheral to the dominant metabolic research front. Bridging this gap through large cardiometabolic trials with psychiatric co-primary endpoints represents a key priority for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.